# The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

> **NCT00002366** · PHASE2 · COMPLETED · sponsor: **Abbott**

## Conditions studied

- Sarcoma, Kaposi
- HIV Infections

## Interventions

- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT00002366
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002366, "The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00002366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*